Cefprozil
- Generic Name
- Cefprozil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H19N3O5S
- CAS Number
- 92665-29-7
- Unique Ingredient Identifier
- 1M698F4H4E
- Background
Cefprozil is a cephalosporin antibiotic that is commonly employed to treat a variety of bacterial infections, including those of the ear and skin, bronchitis, and others.
- Indication
For the treatment of the following infections (respiratory, skin, soft tissue, UTI, ENT) caused by; S. pneumoniae, H. influenzae, staphylococci, S. pyogenes (group A beta-hemolytic streptococci), E. coli, P. mirabilis, Klebsiella sp, coagulase-negative staph
- Associated Conditions
- Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB), Bacterial Infections, Community Acquired Pneumonia (CAP), Streptococcal Pharyngitis, Tonsillitis streptococcal, Urinary Tract Infection, Bacterial otitis media, Uncomplicated skin and subcutaneous tissue bacterial infections
- Associated Therapies
- -
Short Versus Standard of Care Antibiotic Duration for Children Hospitalized for CAP
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Medical College of Wisconsin
- Target Recruit Count
- 236
- Registration Number
- NCT06494072
- Locations
- 🇺🇸
Childrens Wisconsin, Milwaukee, Wisconsin, United States
Cefprozil 500 mg Tablets Under Fed Conditions
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Teva Pharmaceuticals USA
- Target Recruit Count
- 39
- Registration Number
- NCT00840866
- Locations
- 🇺🇸
Gateway Medical Research, Saint Charles, Missouri, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath